SCHEMBL4526092

SCHEMBL4526092

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(Cc3cccc(Cl)c3)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 3/20 0.45
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
UBE2N P61088 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CDK1 P06493 3/20 0.39
PRKCA P17252 2/20 0.39
MAPK1 P28482 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CNR1 P21554 1/20 0.38
GRM1 Q13255 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531049 0.92 HPGD (0.46) YTHDC1NPC1SMN1; SMN2HTTADORA2A
SCHEMBL4505408 0.91 YTHDC1 (0.46) YTHDC1NPC1SMN1; SMN2CNR1MAOA
SCHEMBL4521275 0.91 ALDH1A3 (0.44) YTHDC1CDK1CNR1MAOAMAOB
SCHEMBL4520999 0.91 NPC1 (0.44) YTHDC1NPC1ADORA2AADORA1CNR1
SCHEMBL4511448 0.89 HSD17B10 (0.47) YTHDC1SMN1; SMN2HTTMAPK1ADORA2A
SCHEMBL4521578 0.89 TP53 (0.42) YTHDC1CDK1PRKCAMAOAMAOB
SCHEMBL4517002 0.89 YTHDC1 (0.48) YTHDC1NPC1CDK1PRKCA
SCHEMBL4509737 0.87 CNR1 (0.38) YTHDC1NPC1HTTMAPK1CNR1
SCHEMBL4520072 0.86 MAT2A (0.38) YTHDC1NPC1HTTCNR1HPGD
SCHEMBL4525433 0.85 POLB (0.37) YTHDC1NPC1HTTCDK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 YTHDC1 4699/4885NPC1 631/4885SMN1; SMN2 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.